118 related articles for article (PubMed ID: 14632772)
1. Core-binding factor-beta positive acute myeloid leukaemia cells induce T-cell responses.
Banat GA; Ihlow K; Usluoglu N; Hoppmann S; Hoeck M; Pralle H
Br J Haematol; 2003 Dec; 123(5):819-29. PubMed ID: 14632772
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes.
Banat GA; Usluoglu N; Hoeck M; Ihlow K; Hoppmann S; Pralle H
Br J Haematol; 2004 Aug; 126(4):593-601. PubMed ID: 15287954
[TBL] [Abstract][Full Text] [Related]
3. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
[TBL] [Abstract][Full Text] [Related]
4. CD80 (B7-1) expression on human acute myeloid leukaemic cells cultured with GM-CSF, IL-3 and IL-6.
Hicks C; Keoshkerian E; Gaudry L; Lindeman R
Cancer Immunol Immunother; 2001 Jun; 50(4):173-80. PubMed ID: 11459169
[TBL] [Abstract][Full Text] [Related]
5. Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission.
Whiteway A; Corbett T; Anderson R; Macdonald I; Prentice HG
Br J Haematol; 2003 Feb; 120(3):442-51. PubMed ID: 12580958
[TBL] [Abstract][Full Text] [Related]
6. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia.
Vollmer M; Li L; Schmitt A; Greiner J; Reinhardt P; Ringhoffer M; Wiesneth M; Döhner H; Schmitt M
Br J Haematol; 2003 Mar; 120(6):1000-8. PubMed ID: 12648070
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of CD40 and CD80 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
Li L; Schmitt A; Reinhardt P; Greiner J; Ringhoffer M; Vaida B; Bommer M; Vollmer M; Wiesneth M; Döhner H; Schmitt M
Cancer Immun; 2003 Jul; 3():8. PubMed ID: 12862419
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.
Choudhury BA; Liang JC; Thomas EK; Flores-Romo L; Xie QS; Agusala K; Sutaria S; Sinha I; Champlin RE; Claxton DF
Blood; 1999 Feb; 93(3):780-6. PubMed ID: 9920826
[TBL] [Abstract][Full Text] [Related]
9. Efficient generation of antileukemic autologous T cells by short-term culture and gamma-irradiation of myeloid leukemic cells.
Vereecque R; Saudemont A; Depil S; Corm S; Andrieux J; Soenen-Cornu V; Quesnel B
Cancer Immunol Immunother; 2004 Sep; 53(9):793-8. PubMed ID: 15098140
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT; Mallet F; Sainty D; Maraninchi D; Gastaut JA; Olive D
Eur J Immunol; 1998 Jan; 28(1):90-103. PubMed ID: 9485189
[TBL] [Abstract][Full Text] [Related]
11. Restimulation of tumour-specific immunity in a patient with AML following injection with B7-1 positive autologous blasts.
Hicks C; Cheung C; Lindeman R
Leuk Res; 2003 Nov; 27(11):1051-61. PubMed ID: 12859998
[TBL] [Abstract][Full Text] [Related]
12. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
[TBL] [Abstract][Full Text] [Related]
13. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells.
Notter M; Willinger T; Erben U; Thiel E
Blood; 2001 May; 97(10):3138-45. PubMed ID: 11342441
[TBL] [Abstract][Full Text] [Related]
14. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
15. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses.
Brouwer RE; van der Hoorn M; Kluin-Nelemans HC; van Zelderen-Bhola S; Willemze R; Falkenburg JH
Hum Immunol; 2000 Jun; 61(6):565-74. PubMed ID: 10825585
[TBL] [Abstract][Full Text] [Related]
16. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
[TBL] [Abstract][Full Text] [Related]
17. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses.
Koya RC; Kasahara N; Pullarkat V; Levine AM; Stripecke R
Leukemia; 2002 Sep; 16(9):1645-54. PubMed ID: 12200676
[TBL] [Abstract][Full Text] [Related]
18. Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity.
Yanagita S; Hori T; Matsubara Y; Ishikawa T; Uchiyama T
Br J Haematol; 2004 Feb; 124(4):454-62. PubMed ID: 14984494
[TBL] [Abstract][Full Text] [Related]
19. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
20. Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.
Pettit SJ; Ali S; O'Flaherty E; Griffiths TR; Neal DE; Kirby JA
Clin Exp Immunol; 1999 Apr; 116(1):48-56. PubMed ID: 10209504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
